Endocrine Abstracts

Objectives: An increased risk of birth defects with the use of antithyroid drugs (ATDs) in early pregnancy has been found in large epidemiological studies. It remains debatable whether this risk associates with the medical treatment, maternal thyroid function or thyroid autoimmunity. We aimed to evaluate the risk of birth defects in relation to maternal thyroid function and thyroid autoantibodies in early pregnancy.Methods: Retrospective study including ...

Objective: The prognosis of patients with metastasized and radioactive iodine refractory non-medullary thyroid cancer (NMTC) is poor and treatment options are limited. In NMTC tumors, myeloid cells, such as tumor-associated macrophages, are abundant and have an immunosuppressive and pro-tumoral phenotype. Trained immunity describes a specific epigenetic and metabolic program in innate immune cells that leads to an increased proinflammatory phenotype. The aim of the present stu...

Recent advances in drug discovery and development allowed the identification of THRβ-selective thyromimetic TG68 as a powerful lipid lowering and anti-amyloid agent. To expand our knowledge on the therapeutic potential of this novel thyromimetic, we investigated its anti-inflammatory effects in in vitro human models of neuroinflammation. Subsequently, we performed in vivo studies on high fat diet (HFD) obese/insulin resistant mice, a well-established mod...

Objectives: Although antithyroid drugs (ATD) offer potent therapeutic benefits for treating Graves’ disease (GD), they can occasionally lead to rare, potentially life-threatening adverse events (AEs), such as agranulocytosis or toxic hepatitis. As the incidence and characteristics of these life-threatening AEs in Korea have not been widely investigated, we aimed to identify the real-world features of ATD-related severe AEs.Method: We analyzed 19,975...

Background: Anaplastic thyroid cancer (ATC) is a lethal tumor with a median overall survival of 6 months. In about 30-40% of cases, a BRAFV600E mutation is present. In 2018 dabrafenib and trametinib (D/T) have been approved in USA for BRAFV600E-mutated ATC, while no approval has been obtained so far in Europe. Up to December 2022, D/T were provided by the company for BRAF-altered cancers within a compassionate named program. Here we report the results fro...

Objective: Thyroid hormone receptors (TRs) are important ligand-dependent regulators of thyroid hormone target gene expression. In contrast, the role of TRα2, a thyroid hormone receptor α splice variant that is unable to bind thyroid hormones, remains enigmatic for more than 30 years. However, its evolutionary conservation in eutherian mammals and high expression levels in some cell types as well as under ‘pathological conditions’ such as heart failure stro...